• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

3v.org

Venture Capital Matters

  • Pitch a Startup
    • Make a Contribution
  • Market Reports
  • Technologies
    • Technology Events
  • Domain Names for Startups
  • About
  • Contact

Emergex Raises More Than US$11 Million in a Series A Round to Progress Its Pipeline of Set-Point Vaccines for Infectious Diseases

January 9, 2020 By admin Leave a Comment

Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company developing set-point vaccines to prevent serious infectious diseases, today announced that it has secured over US$11 million in a Series A round. Vickers Venture Partners (‘Vickers’), a top-ranked global early stage Venture Capital company led the round and Dr. Finian Tan, Chairman of Vickers Venture Partners, will join the Emergex Board as a non-executive director.

Founded in 2016, Emergex focuses on developing vaccines that prevent virulent diseases such as Zika, Dengue Fever, Ebola and even pandemic Flu. The Company’s set-point vaccines deliver experimentally-derived pathogen peptide data via quantum-sized nanoclusters to prime the immune system to recognise subsequent infections, mimicking natural infection and preventing severe manifestation of the disease. Emergex’s T-cell vaccines elicit different responses than traditional antibody-producing vaccines, eliminating allergic, autoimmune or antibody-mediated side effects.

Emergex’s underlying platform technology enables rapid development of vaccines to entire families of pathogens, compared to traditional approaches that can take years to develop and scale vaccines for single pathogens. As purely synthetic vaccines with no biological components, Emergex’s vaccines are much safer as they carry no infection risk from live attenuated pathogens; are much cheaper to produce since they do not require culturing; and can be conveniently transported and administered even in remote parts of the world as they can be stored and handled at room temperature.

The financing supports the progress of Emergex’s development pipeline, including a first-in-man Phase 1 clinical trial of its Flavivirus (Dengue) vaccine in Switzerland, as well as Phase 1b clinical trials in the endemic regions of Singapore and Brazil. Proceeds will also support the Universal Influenza and Filovirus programmes through the preclinical stages and early clinical trials. In parallel, Emergex will continue to identify peptide libraries for a range of infectious disease indications to further expand and diversify the Company’s development pipeline.

Professor Thomas Rademacher, CEO and co-founder of Emergex, commented, “Attracting such high calibre investors is an endorsement of our development pipeline and validation of the potential our technologies hold in the field of infectious diseases. These new funds will support us to achieve some significant value-enhancing milestones as we progress our lead vaccine candidates into clinical development.”

In addition to leading this financing, Vickers Venture Partners will assist Emergex with growth at the strategic level, by leveraging its experienced team of technical experts who have a strong track record in helping life science companies raise capital and scale up, and connecting Emergex to its networks of investment and industry partners.

Dr Finian Tan, Chairman of Vickers Venture Partners and a new Emergex non-executive director, added, “With today’s rising global population, the risk posed by infectious diseases is greater than ever before. As such, it is vital that we value and pursue innovation to ensure we have effective healthcare options. We see great potential in Emergex’s technology as it allows vaccines to be produced quickly, administered easily and sold at a fraction of current prices. We believe that this would revolutionize the entire world of vaccines and increase access to a larger number of people around the world.”

Over the last year, Emergex achieved significant milestones, including demonstrating an excellent safety profile for the base particle that will be used for all its vaccines and an excellent safety profile for the final dengue vaccine construct. The Company also signed a collaboration agreement with A*STAR’s IMCB in Singapore to develop a vaccine for Hand, Foot & Mouth disease, and secured a state-of-the-art R&D facility at Milton Park near Oxford, bringing in-house its own up-stream capabilities to drive development of its vaccines.

About Emergex

Emergex, a UK-based biotechnology company headquartered in Abingdon, UK, is pioneering the development of set-point vaccines to address some of the world’s most immediate health threats such as Dengue Fever, Zika, Ebola, pandemic flu and serious intra-cellular bacterial infections.

These set-point vaccines are population based and modify the initial immune status of recipients in a way that ‘primes’ their immune systems to recognise subsequent infectious agents much like a natural infection would do, preventing an acute or severe manifestation of the disease.

Emergex combines validated technologies together with the very latest scientific insights to develop its vaccines, including using synthetic peptide codes determined on actual infected cells and using a proprietary gold nanoparticle carrier system for programming.

The Company has a growing pipeline of vaccine candidates. The most advanced development programme is a vaccine for Dengue Fever, which may also be disease modifying for other Flaviviruses such as the Zika and Yellow Fever viruses. Emergex also has programmes in development for a universal Influenza vaccine and a universal Filovirus vaccine (including viruses such as Ebola and Marburg) and discovery programmes for a Yellow Fever Booster vaccine and a Chikungunya vaccine.

Emergex has partnered with the Institute of Molecular and Cell Biology (IMCB) of Singapore to develop a vaccine for the emerging threat of Hand, Foot and Mouth (HFM) disease and has signed a Memorandum of Understanding (MoU) with Brazil-based Oswaldo Cruz Foundation ‘Fiocruz’ for the development of viral vaccines. This initially covers the development of a vaccine that universally targets diseases within the flavivirus family such as Dengue Fever, Zika and Yellow Fever but could be expanded to include the development of vaccines to target other viral families that are endemic to the region.

Find out more online at www.emergexvaccines.com.

Filed Under: PR Tagged With: Emergex Vaccines, antibody-producing vaccines, set-point vaccines

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Market Analysis

Bread Starters as Online Business
eWaste Reclamation: Electronic waste is a huge problem
Google is working hard to match Apple’s ecosystem integrations
Australia approves a drought-tolerant genetically modified strain of wheat for use in food
Military Applications of Quantum Technology
Portuguese wine market is booming
Solar and wind costs are now competitive with fossil fuels

Market Research Media

BigTechMatters.com: Big Tech Matters
Resilient Supplies: AI is the name of the game
The Luxury Industry: Accelerating and Advancing Corporate Responsibility to Meet Evolving Consumer Demands
ESGFT.com (ESG Fungible Tokens): Companies are doubling down on ESG
Inflation Bites: The U.S. government can buy fewer infrastructure today
SetupMarketplace.com: Setup Marketplace
HashtagSmartphone.com (#Smartphone): How smart assistants will synchronize your life

Secondary Sidebar

Technologies

Technology Segment is the Largest Creator of Value
Digital trends shaping the future of work
Technology sector jumped to a market value of over $13 trillion during the pandemic
A new type of battery could finally make electric cars as convenient and cheap as gas ones
Quantum-enabled technologies could put the world on track to becoming net-zero

Tech Events

Powerful Keynote Speakers, Musical Headliners Announced for Ignite 2021 Logistics Tech Conference, August 3-5, 2021, San Antonio
KubeCon+CloudNativeCon, October 11-15, 2021, in person in Los Angeles or virtually
MATLAB EXPO 2022 Online Conference, May 17–18, 2022
ISACA’s First-ever Virtual EuroCACS 2020 Conference Highlights Opportunities and Risk of Emerging Technologies, 28-30 October 2020
MWC is back and taking place on 28 June – 1 July 2021 in Barcelona

Footer

Recent Posts

  • Plant-based food innovation company, TMRW Foods, raises C$2 million and prepares for North American launch with Sprouts Farmers Market
  • How to achieving gender balance in management teams
  • When you feel like you’re spiraling
  • After Successful Tax Season, Embedded Tax Platform April Raises $30M Series A from Fintech Veterans
  • Vita Mojo Raises US$30 Million to Help Restaurant and Hospitality Chains in Europe Tackle the Digital Future
  • Nautical Commerce Raises $30M to Scale Multi-Vendor Marketplace Technology
  • Token Announces $13 Million Series B Funding Round and Appointment of New CEO to Disrupt the Authentication Market
  • Konnecto Raises $21M to establish a new category in marketing technology
  • Sharebite, the Leading Food Benefits Platform, Announces Closing of $39 Million Series B Round
  • Illumina Invests in £30M Venture Fund to Advance Breakthroughs in Human Health

Dossier

German total mkt cap as % of global mkt cap has hit another all-time low
Arvind Krishna Elected IBM Chairman
Orpheus, by McKinsey, named global leader in procurement analytics by industry analysts, attaining top spot in Spend Matters reviews
Thoma Bravo buys control of Applitools in $300m deal
The BMW Group and AWS Team Up to Accelerate Data-Driven Innovation in the Automotive Industry

Press Media Release

Bezos Earth Fund Announces First Commitments to Marine Protection at UN Ocean Conference
Apple Fitness+ Welcomes People at Every Fitness Level to Train Their Bodies and Minds with Meditation and New Workouts Available September 27
Moderna Confirms 40 Million COVID-19 Vaccine Dose Supply Agreement with the Government of the Republic of Korea
Coding Digest
What is the most disrupted occupation in marketing and public relations?

App Coding

web3 iteration of the internet
Lumigo expands its serverless observability platform to support any modern cloud application
Jotform Store Builder launches as a no-code solution to build a store in minutes
NLP techniques are bridging the gap between text documents
Is Android Studio an Easy IDE Platform to Launch Applications? GoodFirms Review

API Coding

Five Steps to a Secure Cloud Architecture
DataGrail Launches API & Agent to Automate DSR Fulfillment Across All Internal Data Systems, Saving Companies Weeks of Engineering Time
Fintech AI Leader Photon Commerce Partners With Identifee to Enable Banks to Instantly Digitize and Analyze Statements
Types of API Testing
Difference between REST and GraphQL

Copyright © 2022 3v.org

Technologies, Market Analysis & Market Research

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT